Additional risk minimisation measures are product-specific tools that go beyond routine measures when the latter alone are insufficient to adequately limit a relevant medicinal product risk. They are justified in the Risk Management Plan (RMP), tailored to specific safety concerns, and tested for effectiveness following implementation. Their objective is not the collection of further safety data, but rather the reduction of the probability or severity of harm during use.<\/p>\n
Routine risk minimisation measures include product information, the package leaflet, labelling, pack size, and prescription status. These elements generally reach all users of a medicinal product and form the baseline level of risk management. Additional measures are considered when the risk, the target group, or the required course of action exceeds this standard communication. The choice must be appropriate for the type of risk, the healthcare delivery pathway, and the behaviour of the stakeholders involved.<\/p>\n
An additional component must not merely repeat information. Its content should support the specific decision or action that actually influences the risk, such as correct dose selection, recognition of a warning sign, or avoidance of contraindicated use. Before introduction, the target group, distribution, updates, language, and responsibilities must be defined. Inaccessible material or unclear responsibilities can significantly reduce the impact of a measure that is otherwise suitable.<\/p>\n
Educational and safety information tools are aimed at healthcare professionals or patients. These include guides, checklists, patient alert cards, and patient diaries. They can structure special monitoring, counselling, or self-observation. The content must be understandable, product-specific, and consistent with the Summary of Product Characteristics and Package Leaflet; it must not create conflicting recommendations for use.<\/p>\n
In contrast, controlled access tools restrict or manage access to a high-risk application. Examples include the qualification of a specialist, the accreditation of a facility, or traceability requirements. Such instruments are only appropriate if their additional burden is in reasonable proportion to the risk. Implementation requires processes that document who verified the prerequisites and how deviations are to be handled.<\/p>\n
Additional risk minimisation measures are not the pharmacovigilance plan. The pharmacovigilance plan is intended to expand knowledge about a risk; risk minimisation is intended to influence the occurrence or consequences of the risk. A study may investigate the effectiveness of a patient alert card, but the card itself is not a research activity. Both instruments may appear in the same RMP, but they must have separate objectives and success criteria.<\/p>\n
The Summary of Product Characteristics is also not an additional measure in itself, but belongs to the routine level. An additional measure only exists when, for an individual medicinal product, further actions such as an educational programme, controlled access, or a patient alert card are required. This distinction is important because a separate justification and evaluation are expected only for the added benefit beyond the standard information.<\/p>\n
Measuring success should distinguish between two levels. Process indicators show, for example, whether guides were distributed or qualifications were documented. Outcome indicators verify whether the target group understands the central safety message or whether the target behaviour to be prevented has changed. A high distribution rate therefore does not prove risk reduction. Conversely, low reach can explain why an instrument with appropriate content remains without visible effect. Indicators must be realistically compatible with available data sources and the intended healthcare delivery pathway during the design phase.<\/p>\n
In the event of changes to the indication, target population, or product information, the measure must be re-evaluated for suitability. A guide that was originally appropriate may become incomplete due to a new dosage, an additional area of application, or altered care pathways. Updating and controlled redistribution are therefore part of actual risk management.<\/p>\n
Feedback from the healthcare setting can also show whether an instrument is misunderstood, practically unavailable, or undermined by other processes.<\/p>\n
For clinical programmes, planned additional measures can influence the collection of relevant data even during development. It must be verified whether patients understand the intended materials, whether trial sites can realistically implement the desired workflow, and which data will later prove the effectiveness of the instrument. In this context, study materials must not be inadvertently anticipated as a marketing authorisation measure if their purpose is merely the protocol-compliant conduct of the study.<\/p>\n
Full-service CROs like Mediconomics provide support for target group analyses, the operational planning of educational materials, coordination with Medical Writing and Regulatory Affairs, and the preparation of effectiveness indicators. For control instruments, they can integrate workflows for proof of qualification, site documentation, and traceability into the study and healthcare processes.<\/p>\n
Are patient alert cards always additional risk minimisation?<\/strong><\/p>\n No. They are only used when a product-specific safety concern justifies such additional support.<\/p>\n What distinguishes a control tool from a guide?<\/strong><\/p>\n A guide conveys information; a control tool links access or use to verifiable prerequisites such as qualification or accreditation.<\/p>\n How is the impact of additional measures evaluated?<\/strong><\/p>\n The RMP provides for suitable indicators with which the implementation and influence of the measure on the targeted risk behaviour can be verified.<\/p>\n Additional risk minimisation measures are product-specific tools that go beyond routine measures when the latter alone are insufficient to adequately limit a relevant medicinal product risk. They are justified in the Risk Management Plan (RMP), tailored to specific safety concerns, and tested for effectiveness following implementation. Their objective is not the collection of further safety […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[23],"class_list":["post-8040","glossary","type-glossary","status-publish","hentry","glossary-cat-pharmakovigilanz"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8040\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=8040"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=8040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n